Matches in SemOpenAlex for { <https://semopenalex.org/work/W2298049278> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2298049278 endingPage "8" @default.
- W2298049278 startingPage "8" @default.
- W2298049278 abstract "From 2001 to 2013 eleven patients with relapsed acute promyelocytic leukemia (APL) (median age – 30 years) received arsenicum trioxide (ATO). ATO was administered as a 2nd line relapse therapy in 9 patients, as 1st line relapse therapy in 2 patients. ATO was administered in a dose of 0.1 mg/kg in 7 patients, 0.15 mg/kg – in 4 patients. The induction duration was 14 days in 3 patients, 24–35 days in 2 patients, 60 days in 6 patients. From the 1st day of ATO patients received 45 mg/m2 all trans retinoic acid (ATRA) (1 patient – from day 29 of ATO therapy). Maintenance therapy ATO + ATRA (10–14 days courses, every four weeks) patients were receiving during 10–15 months. 2 from 3 patients with molecular relapses achieved remission lasting 57 and 89 months after the 14-day ATO courses. 1 from 2 patients with bone marrow relapse achieved remission lasting 27 months after the 24–35-day ATO courses. 60-day courses were effective in 5 of 6 patients: in 4 of which remission are retained during 16, 19, 27, 57 months; 1 patient was relapsed after 12 months; 1 patient did not achieve molecular remission. 3 patients received allogeneic hematopoietic stem cell transplantation (alloHSCT), 2 of which alive in remission. 1 patient received autologous hematopoietic stem cell transplantation in the 2nd molecular remission (alive in remission). 4 patients died: 1 – in the 3rd relapse (duration of 2nd remission – 9 months), 1 – in remission from complications after alloHSCT, 1 – from APL progression, 1 – sudden death in 2nd remission lasting 72 months. ATO + ATRA for 60 days with supportive therapy are more effective than chemotherapy in the treatment of APL relapse. Interferon α + ATRA are inappropriate treatment of APL molecular and cytogenetic relapse. Using autologous HSCT in 2nd molecular remission will improve the results of APL relapse treatment." @default.
- W2298049278 created "2016-06-24" @default.
- W2298049278 creator A5008276842 @default.
- W2298049278 creator A5014421357 @default.
- W2298049278 creator A5030043766 @default.
- W2298049278 creator A5042955114 @default.
- W2298049278 creator A5049678454 @default.
- W2298049278 date "2015-06-04" @default.
- W2298049278 modified "2023-10-14" @default.
- W2298049278 title "Combination of arsenicum trioxide and all trans retinoic acid in the treatment of relapsed acute promyelocytic leukemia" @default.
- W2298049278 doi "https://doi.org/10.17650/1818-8346-2015-10-2-8-13" @default.
- W2298049278 hasPublicationYear "2015" @default.
- W2298049278 type Work @default.
- W2298049278 sameAs 2298049278 @default.
- W2298049278 citedByCount "1" @default.
- W2298049278 countsByYear W22980492782019 @default.
- W2298049278 crossrefType "journal-article" @default.
- W2298049278 hasAuthorship W2298049278A5008276842 @default.
- W2298049278 hasAuthorship W2298049278A5014421357 @default.
- W2298049278 hasAuthorship W2298049278A5030043766 @default.
- W2298049278 hasAuthorship W2298049278A5042955114 @default.
- W2298049278 hasAuthorship W2298049278A5049678454 @default.
- W2298049278 hasBestOaLocation W22980492781 @default.
- W2298049278 hasConcept C104317684 @default.
- W2298049278 hasConcept C126322002 @default.
- W2298049278 hasConcept C141071460 @default.
- W2298049278 hasConcept C185592680 @default.
- W2298049278 hasConcept C2776601000 @default.
- W2298049278 hasConcept C2776694085 @default.
- W2298049278 hasConcept C2777408962 @default.
- W2298049278 hasConcept C2779963572 @default.
- W2298049278 hasConcept C2781121885 @default.
- W2298049278 hasConcept C2911091166 @default.
- W2298049278 hasConcept C3018657049 @default.
- W2298049278 hasConcept C55493867 @default.
- W2298049278 hasConcept C71924100 @default.
- W2298049278 hasConcept C90924648 @default.
- W2298049278 hasConceptScore W2298049278C104317684 @default.
- W2298049278 hasConceptScore W2298049278C126322002 @default.
- W2298049278 hasConceptScore W2298049278C141071460 @default.
- W2298049278 hasConceptScore W2298049278C185592680 @default.
- W2298049278 hasConceptScore W2298049278C2776601000 @default.
- W2298049278 hasConceptScore W2298049278C2776694085 @default.
- W2298049278 hasConceptScore W2298049278C2777408962 @default.
- W2298049278 hasConceptScore W2298049278C2779963572 @default.
- W2298049278 hasConceptScore W2298049278C2781121885 @default.
- W2298049278 hasConceptScore W2298049278C2911091166 @default.
- W2298049278 hasConceptScore W2298049278C3018657049 @default.
- W2298049278 hasConceptScore W2298049278C55493867 @default.
- W2298049278 hasConceptScore W2298049278C71924100 @default.
- W2298049278 hasConceptScore W2298049278C90924648 @default.
- W2298049278 hasIssue "2" @default.
- W2298049278 hasLocation W22980492781 @default.
- W2298049278 hasLocation W22980492782 @default.
- W2298049278 hasOpenAccess W2298049278 @default.
- W2298049278 hasPrimaryLocation W22980492781 @default.
- W2298049278 hasRelatedWork W1996373554 @default.
- W2298049278 hasRelatedWork W2046287739 @default.
- W2298049278 hasRelatedWork W2069245535 @default.
- W2298049278 hasRelatedWork W2090996900 @default.
- W2298049278 hasRelatedWork W2094319709 @default.
- W2298049278 hasRelatedWork W2364398761 @default.
- W2298049278 hasRelatedWork W2369395861 @default.
- W2298049278 hasRelatedWork W2374276421 @default.
- W2298049278 hasRelatedWork W2382466782 @default.
- W2298049278 hasRelatedWork W2383758775 @default.
- W2298049278 hasVolume "10" @default.
- W2298049278 isParatext "false" @default.
- W2298049278 isRetracted "false" @default.
- W2298049278 magId "2298049278" @default.
- W2298049278 workType "article" @default.